摘要
头孢洛林酯是新型注射给药的广谱头孢菌素类抗生素,对革兰阳性菌,包括耐甲氧西林金黄色葡萄球菌(MRSA)和多药耐药肺炎链球菌(MDRSP)以及常见革兰阴性菌具有杀菌活性。2010年10月29日,美国FDA批准其用于治疗成人社区获得性细菌肺炎(CABP)和急性细菌皮肤和皮肤结构感染(ABSSSI),包括MRSA的感染。文中对其抗菌活性、药动学/药效学、临床疗效、不良反应等做一综述。
Ceflaroline fosamil is a novel, parenteral, broad-spectrum cephalosporin exhibiting bactericidal activity against Gram-positive organisms, including MRSA and multidrug-resistant Streptococcus pneumoniae （MDRSP）, as well as common Gram-negative pathogens. On Oct. 29, 2010, the U.S. Food and Drug Adminis- tration approved ceftaroline fosamil to treat adults with community acquired bacterial pneumonia （CABP） and acute bacterial skin and skin structure infections （ABSSSI） , including methicillin-resistant Staphylococcus aureus （MR- SA）. The chemistry and structure-activity relationship, antibacterial activity, pharmacokinetics, pharmacodynam- ics, therapeutic efficacy, adverse effects were reviewed in this paper.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2012年第2期109-113,123,共6页
Chinese Journal of New Drugs
关键词
头孢洛林酯
革兰阳性耐药菌
社区获得性细菌肺炎
急性细菌皮肤和皮肤结构感染
ceflaroline fosamil
resistant Gram-positive pathogens
community acquired bacterial pneumo- nia （CABP）
acute bacterial skin and skin structure infections （ABSSSI）
